Ivonescimab Meets HARMONi-2 Overall-Survival Endpoint
Akeso reported that first-line ivonescimab monotherapy produced a statistically significant overall-survival benefit versus pembrolizumab in HARMONi-2, a randomized, double-blind Phase III study in 398 patients with PD-L1-positive advanced non-small-cell lung cancer in China. The…
